Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

R906289 Monosodium (R289 Na)

PreclinicalSmall molecule

RRigel Pharmaceuticals

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Risk Myelodysplastic SyndromesRecruiting

Low Risk Myelodysplastic SyndromesPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Low Risk Myelodysplastic Syndromes

NCT05308264

Clinical

Trials by Indication[1]

Low Risk Myelodysplastic Syndromes1 trial

An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Who Are Relapsed/Refractory/Resistant to Prior Therapies

Recruiting·RRigel Pharmaceuticals·Preclinical·NCT05308264·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for R906289 Monosodium (R289 Na). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R906289 Monosodium (R289 Na) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R906289 Monosodium (R289 Na). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rigel Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRigel Pharmaceuticals

Related News